ArticleCureus2025
Outcomes of Bronchial Artery Embolization in Patients With Moderate to Severe Hemoptysis: A Longitudinal Study From a Tertiary Care Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemoptysis, particularly in its moderate to severe forms, is a life-threatening respiratory emergency with multiple underlying etiologies, including post-tuberculosis sequelae, bronchiectasis, and aspergilloma. Bronchial artery embolization (BAE) has emerged as a first-line, minimally invasive intervention for controlling bleeding, but long-term outcomes and recurrence rates vary across populations, particularly in tuberculosis-endemic regions.
methodsThis longitudinal observational study was conducted over 18 months at a tertiary care center, enrolling 203 patients aged 18 years or older presenting with moderate to massive hemoptysis. All patients underwent clinical evaluation, radiological imaging, and BAE using Embox (Meril Life Sciences Pvt. Ltd., Vapi, India). Demographics, etiology, vessel involvement, immediate and follow-up outcomes at one and three months, and complications were recorded. The primary endpoint was immediate clinical success (bleeding cessation within 24 hours), while secondary endpoints included recurrence, treatment failure, and complication rates.
resultsModerate hemoptysis was observed in 119 (58.6%) patients, while massive hemoptysis occurred in 84 (41.4%). Aspergilloma was the most common underlying etiology, identified in 89 (43.8%) cases, followed by bronchiectasis in 39 (19.2%) and fibrocavitary lesions in 24 (11.8%). Bilateral bronchial artery involvement was seen in 64 (27.8%) patients. The overall immediate clinical success rate was 151 (74.3%), whereas recurrence or treatment failure occurred in 22 (10.8%) patients, and mortality was reported in seven (3.4%) cases. Postprocedural complications were common, with chest pain in 119 (58.6%) and fever in 30 (14.8%) patients. Severe neurological events were rare, occurring in only one patient (0.5%). Most complications were self-limiting and showed a declining trend over time.
conclusionBAE is an effective and relatively safe intervention for controlling moderate to massive hemoptysis, particularly in patients with post-tuberculosis sequelae. Although recurrence and minor complications are common, BAE offers a valuable treatment modality in both emergency and elective settings, especially for patients unfit for surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.